Tirtha Chakraborty - Feb 6, 2023 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Role: Chief Scientific Officer
Signature: /s/ Rich Segal, Attorney-in-Fact
Stock symbol: VOR
Transactions as of: Feb 6, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/8/2023, 03:18 PM
Previous filing: Sep 6, 2022
Next filing: Mar 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VOR	Common Stock	Award	$0	+47.8K	+47.76%	$0.00	148K	Feb 6, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VOR	Employee Stock Option (right to buy)	Award	$0	+95.5K		$0.00	95.5K	Feb 6, 2023	Common Stock	95.5K	$5.55	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning February 6, 2023, subject to the Reporting Person's continued service as of each such date.
F2	Includes 3,000 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on November 15, 2022.
F3	The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date.